— Case Study —

Using EMA Scientific Advice to Strengthen Development Strategy and Investor Readiness

Introduction

Early-stage pharmaceutical companies often face the challenge of demonstrating a clear and credible development pathway to investors while navigating complex regulatory requirements. Securing regulatory feedback at an early stage can significantly reduce development risk, strengthen strategic decision-making, and improve confidence among potential stakeholders. This case study highlights how we supported a virtual pharmaceutical company developing an innovative pain relief product by preparing a comprehensive EMA Scientific Advice strategy and translating regulatory guidance into an investor-ready development plan.

The Challenge

The client was a small virtual company with a novel pain relief product that uses a well-established pain relief ingredient. They required a development plan to present to future investors.

Our Comprehensive Approach

An expert team with EMA scientific advice experience was assigned to collaborate with the client.

Coordinated scientific advice procedure including coaching the client on Scientific Advice Meeting (SAM) best practice.
Facilitated discussions with pharmacokinetics, clinical and in silico-modelling experts.
Reviewed the available development work and identified key areas for discussion with EMA.
Prepared a coherent scientific advice package for submission to EMA.

Benefits

The client gained valuable insight into the development requirements for the product, enabling the preparation of a robust development plan with outline costs for investors.

Detailed advice from Scientific Advice Meeting (SAM)
Expert analysis of minutes provided to the client to assist preparation of the development plan.

Conclusion

The outcome of this project demonstrates the value of early regulatory engagement and expert scientific planning when developing innovative pharmaceutical products. By securing clear guidance from the EMA and translating that feedback into a structured development strategy, we enabled the client to present a credible, investor-ready plan for the continued development of their product.

For companies developing new medicinal products or seeking regulatory scientific advice from the EMA, our team provides expert support in planning development strategies, preparing scientific advice submissions, and translating regulatory feedback into practical next steps for successful product development.

Build a Stronger Development Strategy with EMA Scientific Advice

Early regulatory engagement can reduce development risk, strengthen investor confidence, and provide greater clarity for your clinical and regulatory programme. Our experts help you prepare, manage, and maximise the value of Scientific Advice procedures.